PAO Group Inc (PAOG)

[HNDRXX]

$PAOG Wants FDA Approval (Covid Treatment), Respx Positive Results COVID

Please review DD report Below with the following link.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157193041
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157193041
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157193041
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157193041

PAOG Cannabis Pharma Initiative Stands to Benefit From Senator Marco Rubio and Congresswoman Jenniffer González Colón New Bill

SANDUSKY, Ohio, Aug. 11, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced that the company's ongoing business development initiative in Puerto Rico could benefit from a new bill introduced by Senator Marco Rubio and Congresswoman Jenniffer González Colón.

PAOG recently acquired cannabis pharmaceutical development assets. Simultaneously the company initiated efforts in Puerto Rico to partner with a Contract Research Organization (CRO) to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for PAOG's newly acquired RespRx, a treatment for Chronic Obstructive Pulmonary Disease (COPD).

The market for COPD treatment is anticipated to reach $14 billion by 2025.

Based on positive results from an informal trial of RexpRx with 25 COVID-19 patients, PAOG also plans to make Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

Congresswoman Jenniffer González Colón and Florida Senator Marco Rubio introduced legislation last week to position Puerto Rico as a national production center of medical equipment and drugs.

"The coronavirus pandemic has made it clear that we must rebuild our national manufacturing capacity, especially in our medical industry," Rubio said. "For too long, our manufacturing capabilities have moved to China, impacting communities across our country, including Puerto Rico, which was once home to a strong manufacturing industry in the United States. I am proud to join Congresswoman González-Colón in this vital effort to rebuild our manufacturing capacity, especially in the economically marginalized areas that were most affected by the COVID-19 pandemic. "

The RespRx COPD biopharmaceutical technology is based on U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAGO's RespRx COPD research and development has been submitted under separate patent application and trademark.

An analyst report from Goldman Small Cap Research covering PAOG's Cannabis Biopharmaceutical assets and business strategy is anticipated later this week on Thursday, August 14, 2020.

In the interview, Mr. DiPrima confirms a recently published new PAOG website and the coming publication of PAOG's financial reports. He further confirms the company now has a revenue base with the recent acquisition of a cannabis cultivation operation from Puration, Inc. (PURA). Mr. DiPrima concludes the interview with a discussion of why he believes the PPS is undervalued and that he anticipates a PPS correction when the PAOG financials are published.